Regulatory approval
Published by the Health Canada. Approved
TECENTRIQ (atezolizumab) in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering >= 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | ER negative, HER2-negative, PD-L1 >= 1%, PR negative | Invasive Breast Carcinoma | Atezolizumab, Nab-paclitaxel |